Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Comment by GeneralWolfeon Nov 26, 2021 6:28am
109 Views
Post# 34167754

RE:RE:MEDV is Creating value. FACT

RE:RE:MEDV is Creating value. FACT NO, not the case at all. You are lying again... lolll, but nice try. Again, just facts. Some of the MEDV highlights from the zoom call. -Share Consolidation Passed - R/S was addressed and is “only” if needed to uplist but is not a priority they feel they can hit targets based on increasing and projected revenue going into 2022 -They are on pace for their projected revenue of 60M for 2021 (*From invester deck, looking at Q3 we could very well pass 60 million) -Spoke on Q4: "We anticipate to be just as good if not significantly better than Q3, trend it going in the right direction. Maybe a dip in November, fluctuation of business (10-15% dip from absolute peak)." *Q3 Revenue was $25.3 Million -Spoke to their software ,Govt asking for even more testing, different tests coming at locations, influenza and other tests, Focusing on expanding platforms with AI , Cholesterol and diabetes tech, prescriptions. -States MEDV is grossly undervalued, Says to deal with shorts by producing revenue results and increasing them.
<< Previous
Bullboard Posts
Next >>